596 related articles for article (PubMed ID: 16971522)
21. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
22. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
23. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
Honore P; Wismer CT; Mikusa J; Zhu CZ; Zhong C; Gauvin DM; Gomtsyan A; El Kouhen R; Lee CH; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
J Pharmacol Exp Ther; 2005 Jul; 314(1):410-21. PubMed ID: 15837818
[TBL] [Abstract][Full Text] [Related]
24. K-685, a TRPV1 antagonist, blocks PKC-sensitized TRPV1 activation and improves the inflammatory pain in a rat complete Freund's adjuvant model.
Sugimoto Y; Kojima Y; Inayoshi A; Inoue K; Miura-Kusaka H; Mori K; Saku O; Ishida H; Atsumi E; Nakasato Y; Shirakura S; Toki S; Shinoda K; Suzuki N
J Pharmacol Sci; 2013; 123(3):256-66. PubMed ID: 24162023
[TBL] [Abstract][Full Text] [Related]
25. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM
Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837
[TBL] [Abstract][Full Text] [Related]
26. Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents.
Okun A; DeFelice M; Eyde N; Ren J; Mercado R; King T; Porreca F
Mol Pain; 2011 Jan; 7():4. PubMed ID: 21219650
[TBL] [Abstract][Full Text] [Related]
27. The role of TRPV1 in different subtypes of dorsal root ganglion neurons in rat chronic inflammatory nociception induced by complete Freund's adjuvant.
Yu L; Yang F; Luo H; Liu FY; Han JS; Xing GG; Wan Y
Mol Pain; 2008 Dec; 4():61. PubMed ID: 19055783
[TBL] [Abstract][Full Text] [Related]
28. A distinct role for transient receptor potential ankyrin 1, in addition to transient receptor potential vanilloid 1, in tumor necrosis factor α-induced inflammatory hyperalgesia and Freund's complete adjuvant-induced monarthritis.
Fernandes ES; Russell FA; Spina D; McDougall JJ; Graepel R; Gentry C; Staniland AA; Mountford DM; Keeble JE; Malcangio M; Bevan S; Brain SD
Arthritis Rheum; 2011 Mar; 63(3):819-29. PubMed ID: 21360511
[TBL] [Abstract][Full Text] [Related]
29. Blockade of peripheral P2Y1 receptors prevents the induction of thermal hyperalgesia via modulation of TRPV1 expression in carrageenan-induced inflammatory pain rats: involvement of p38 MAPK phosphorylation in DRGs.
Kwon SG; Roh DH; Yoon SY; Moon JY; Choi SR; Choi HS; Kang SY; Han HJ; Beitz AJ; Lee JH
Neuropharmacology; 2014 Apr; 79():368-79. PubMed ID: 24333674
[TBL] [Abstract][Full Text] [Related]
30. Orally administered selective TRPV1 antagonist, JTS-653, attenuates chronic pain refractory to non-steroidal anti-inflammatory drugs in rats and mice including post-herpetic pain.
Kitagawa Y; Tamai I; Hamada Y; Usui K; Wada M; Sakata M; Matsushita M
J Pharmacol Sci; 2013; 122(2):128-37. PubMed ID: 23728381
[TBL] [Abstract][Full Text] [Related]
31. Impaired nociception and inflammatory pain sensation in mice lacking the prokineticin receptor PKR1: focus on interaction between PKR1 and the capsaicin receptor TRPV1 in pain behavior.
Negri L; Lattanzi R; Giannini E; Colucci M; Margheriti F; Melchiorri P; Vellani V; Tian H; De Felice M; Porreca F
J Neurosci; 2006 Jun; 26(25):6716-27. PubMed ID: 16793879
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
[TBL] [Abstract][Full Text] [Related]
33. Presynaptic inhibition of transient receptor potential vanilloid type 1 (TRPV1) receptors by noradrenaline in nociceptive neurons.
Chakraborty S; Elvezio V; Kaczocha M; Rebecchi M; Puopolo M
J Physiol; 2017 Apr; 595(8):2639-2660. PubMed ID: 28094445
[TBL] [Abstract][Full Text] [Related]
34. Streptozotocin-induced early thermal hyperalgesia is independent of glycemic state of rats: role of transient receptor potential vanilloid 1(TRPV1) and inflammatory mediators.
Bishnoi M; Bosgraaf CA; Abooj M; Zhong L; Premkumar LS
Mol Pain; 2011 Jul; 7():52. PubMed ID: 21794120
[TBL] [Abstract][Full Text] [Related]
35. The role of TRPV1 channels in carrageenan-induced mechanical hyperalgesia in mice.
Watanabe M; Ueda T; Shibata Y; Kumamoto N; Ugawa S
Neuroreport; 2015 Feb; 26(3):173-8. PubMed ID: 25590988
[TBL] [Abstract][Full Text] [Related]
36. The sigma-1 receptor curtails endogenous opioid analgesia during sensitization of TRPV1 nociceptors.
Ruiz-Cantero MC; Cortés-Montero E; Jain A; Montilla-García Á; Bravo-Caparrós I; Shim J; Sánchez-Blázquez P; Woolf CJ; Baeyens JM; Cobos EJ
Br J Pharmacol; 2023 Apr; 180(8):1148-1167. PubMed ID: 36478100
[TBL] [Abstract][Full Text] [Related]
37. TRPV1 antagonists as a potential treatment for hyperalgesia.
Roberts LA; Connor M
Recent Pat CNS Drug Discov; 2006 Jan; 1(1):65-76. PubMed ID: 18221192
[TBL] [Abstract][Full Text] [Related]
38. Fatty-acid-binding protein inhibition produces analgesic effects through peripheral and central mechanisms.
Peng X; Studholme K; Kanjiya MP; Luk J; Bogdan D; Elmes MW; Carbonetti G; Tong S; Gary Teng YH; Rizzo RC; Li H; Deutsch DG; Ojima I; Rebecchi MJ; Puopolo M; Kaczocha M
Mol Pain; 2017 Jan; 13():1744806917697007. PubMed ID: 28326944
[TBL] [Abstract][Full Text] [Related]
39. Activation of TRPV1 in the spinal cord by oxidized linoleic acid metabolites contributes to inflammatory hyperalgesia.
Patwardhan AM; Scotland PE; Akopian AN; Hargreaves KM
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18820-4. PubMed ID: 19843694
[TBL] [Abstract][Full Text] [Related]
40. Inflammation induces Epac-protein kinase C alpha and epsilon signaling in TRPV1-mediated hyperalgesia.
Gu Y; Li G; Huang LM
Pain; 2018 Nov; 159(11):2383-2393. PubMed ID: 30015706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
